InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.370 0.01 (2.78%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$113 Recce Receives Further A$973,144 R&D Advance 4 Apr 2023 10:08AM $0.550 $0.370 fallen by 32.73%
$113 Corporate Presentation - WI Emergence 2023 23 Mar 2023 10:22AM $0.560 $0.370 fallen by 33.93%
$113 Appendix 4D and Interim Financial Report 27 Feb 2023 6:04PM $0.570 $0.370 fallen by 35.09%
$113 Investor Presentation - Spark Plus Biotech Day 24 Feb 2023 10:56AM $0.560 $0.370 fallen by 33.93%
$113 Recce Selects CMAX for Phase I/II UTI Clinical Trial 20 Feb 2023 9:41AM $0.580 $0.370 fallen by 36.21%
$113 Cleansing Statement 14 Feb 2023 2:11PM $0.560 $0.370 fallen by 33.93%
$113 Application for quotation of securities - RCE 14 Feb 2023 2:08PM $0.560 $0.370 fallen by 33.93%
$113 RECCE Trademark Registered - Hong Kong 2 Feb 2023 10:28AM $0.640 $0.370 fallen by 42.19%
$113 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2023 1:28PM $0.650 $0.370 fallen by 43.08%
$113 A$6.21m Received from R&D Rebate Payments 25 Jan 2023 10:27AM $0.650 $0.370 fallen by 43.08%
$113 Cleansing Statement 11 Jan 2023 5:18PM $0.690 $0.370 fallen by 46.38%
$113 Application for quotation of securities - RCE 11 Jan 2023 5:15PM $0.690 $0.370 fallen by 46.38%
$113 JP Morgan Healthcare Conference 10 Jan 2023 12:24PM $0.680 $0.370 fallen by 45.59%
$113 Australian Patent to be Granted for RECCE Anti-Infectives 10 Jan 2023 10:05AM $0.650 $0.370 fallen by 43.08%
$113 Anti-Infective Research Unit est. at Murdoch Children's 15 Dec 2022 11:56AM $0.660 $0.370 fallen by 43.94%
$113 Approval to Start Phase I/II Diabetic Foot Ulcer Study 9 Dec 2022 10:06AM $0.645 $0.370 fallen by 42.64%
$113 Trading Halt 7 Dec 2022 12:53PM $0.645 $0.370 fallen by 42.64%
$113 Pause in Trading 7 Dec 2022 12:44PM $0.645 $0.370 fallen by 42.64%
$113 Change of Director's Interest Notice - A McKeough 15 Nov 2022 5:36PM $0.705 $0.370 fallen by 47.52%
$113 Notification regarding unquoted securities - RCE 15 Nov 2022 5:29PM $0.705 $0.370 fallen by 47.52%
$113 Constitution 14 Nov 2022 6:36PM $0.685 $0.370 fallen by 45.99%
$113 Results of Meeting 14 Nov 2022 4:22PM $0.685 $0.370 fallen by 45.99%
$113 AGM Presentation 14 Nov 2022 1:38PM $0.665 $0.370 fallen by 44.36%
$113 Investor Presentation - Spark Plus Healthcare Day 3 Nov 2022 10:21AM $0.635 $0.370 fallen by 41.73%
$113 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2022 11:48AM $0.690 $0.370 fallen by 46.38%

251 - 275 of 729 results

Page 11 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.